Dendritic Cell Tumor Fusion Vaccination In Conjunction With Autologous Transplantation For Multiple Myeloma
Year: 2010
Type: article
Abstract: Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) offers a unique setting to explore the role of immunotherapy in eradicating malignancy. Our group has developed a cancer vaccine whereby dendritic cells (DCs) are fused with autologous tumor cells. We are conducting a clinical trial in which MM patients undergo ASCT followed by vaccination with 3 doses of DC/MM fusions (cohort 1). A second cohort receives an additional vaccine prior to stem cell collection (cohort 2). To date, 26 patients have been enrolled in cohort 1 and 9 in cohort 2.
Authors: J. Rosenblatt, I. Avivi, B. Vasir, T. Katz, L. Uhl, Z. Wu, P. Somaiya, H. Mills, R.M. Joyce, J.D. Levine, D. Tzachanis, V. Boussiotis, B. Glotzbecker, K. Francoeur, D. Dombagoda, M. Tsumer, L. Bisharat, N. Giallombardo, K. Conway, D. Fitzgerald, R. Barhad, P. Richardson, K.C. Anderson, N.C. Munshi, J.M. Rowe, D. Kufe, D. Avigan
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2127175589